title: Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.
authors.forename: R P
authors.initials: RP
authors.lastname: Byington
authors.forename: T E
authors.initials: TE
authors.lastname: Craven
authors.forename: C D
authors.initials: CD
authors.lastname: Furberg
authors.forename: M
authors.initials: M
authors.lastname: Pahor
mesh_terms: D001161:Arteriosclerosis / Q000188:drug therapy; D001786:Blood Glucose / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology*; D002340:Carotid Artery Diseases / Q000188:drug therapy; D004232:Diuretics; D018149:Glucose Intolerance / Q000150:complications*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications; D017275:Isradipine / Q000009:adverse effects*; D008875:Middle Aged; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004232:Diuretics; D006442:Glycated Hemoglobin; D006852:Hydrochlorothiazide; D017275:Isradipine; D049993:Sodium Chloride Symporter Inhibitors